OMass Therapeutics Announces £27.5 Million Extended Series A Financing
(WorldNews Health)

- Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders - Oxford, 17 February 2020 - OMass Therapeutics (`OMass`), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, today announced completion of an extended Series A financing of £27.5 million from existing investors Syncona Ltd (`Syncona`) and Oxford Sciences...